Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib for the potential treatment of Fibrostenosing Crohn’s Disease.